Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:cobicistat
gptkb:atazanavir |
| gptkbp:approvalYear |
2015-01-29
|
| gptkbp:ATCCode |
J05AR16
|
| gptkbp:combines |
other antiretroviral agents
|
| gptkbp:contraindication |
severe hepatic impairment
concomitant use with certain drugs (e.g., rifampin, St. John's wort) |
| gptkbp:drugClass |
antiretroviral combination
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evotaz
|
| gptkbp:indication |
HIV-1 infection
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:mechanismOfAction |
protease inhibitor (atazanavir) and CYP3A inhibitor (cobicistat)
|
| gptkbp:pregnancyCategory |
consult healthcare provider
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache jaundice rash |
| gptkbp:bfsParent |
gptkb:DB06151
gptkb:DB04876 |
| gptkbp:bfsLayer |
7
|